NGL FINECHEM
Back to Income Statement
|
NGL FINECHEM Last 5 Year Revenue History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Net Sales | ₹368 Cr | ₹339 Cr | ₹278 Cr | ₹318 Cr | ₹258 Cr |
What is the latest Revenue of NGL FINECHEM ?
| Year | Revenue |
|---|---|
| Mar2026 | ₹368 Cr |
| Mar2025 | ₹339 Cr |
| Mar2024 | ₹278 Cr |
| Mar2023 | ₹318 Cr |
| Mar2022 | ₹258 Cr |
How is Revenue of NGL FINECHEM Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2026 | ₹368 Cr | 8.73 | |
| Mar2025 | ₹339 Cr | 21.79 | |
| Mar2024 | ₹278 Cr | -12.42 | |
| Mar2023 | ₹318 Cr | 23.08 | |
| Mar2022 | ₹258 Cr | - | |
Compare Revenue of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,715.0 Cr | -4.7% | 4.2% | 100.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,299.0 Cr | 1% | 7.5% | 7.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹297,325.0 Cr | 0.8% | 22.8% | 71.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹178,727.0 Cr | 0.2% | 1.9% | 20.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹116,145.0 Cr | 0.8% | 12.2% | 12.3% | Stock Analytics | |
| CIPLA | ₹114,312.0 Cr | 1.5% | 6.4% | -7.8% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -4.7% |
4.2% |
100.4% |
| SENSEX | 2.9% |
13.9% |
-0.8% |
You may also like the below Video Courses